Traitement pharmacologique de l'hyperactivité détrusorienne neurologique: injections intra-détrusoriennes de toxine botulique A [Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections].

Details

Serval ID
serval:BIB_E53603061954
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Traitement pharmacologique de l'hyperactivité détrusorienne neurologique: injections intra-détrusoriennes de toxine botulique A [Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections].
Journal
Progrès en Urologie
Author(s)
Karsenty G., Corcos J., Schurch B., Ruffion A., Chartier-Kastler E.
ISSN
1166-7087 (Print)
ISSN-L
1166-7087
Publication state
Published
Issued date
2007
Volume
17
Number
3
Pages
568-575
Language
french
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Abstract
Botulinum toxins are among the most powerful of all natural poisons. They are responsible for human botulism and constitute potential chemical weapons, but are nevertheless used as therapeutic agents in an increasing number of indications and medical specialties. Botulinum toxins were used for the first time in urology by intrasphincteric injection by Dykstra in 1988 to treat detrusor-sphincter dyssynergia in spinal cord injury patients. Schurch performed the first intradetrusor injections in 2000 to treat incontinence due to overactive bladder in adult spinal cord injury or multiple sclerosis patients. This review of the literature presents the results and level of proof for the use of botulinum toxin intradetrusor injection to treat neurogenic voiding disorders. Botulinum toxin A intradetrusor injections constitute a safe, conservative, reversible and short-term effective (6-12 months) alternative after failure of anticholinergic therapy for overactive bladder and its clinical consequences in adult spinal cord injury or multiple sclerosis patients (level 1b) and in children with neural tube defects (level 4). The efficacy of the first injection appears to be maintained at subsequent injections (up to 10 cycles) (level 4). Convergent and longer-term data are necessary to document and more clearly define the medium- and long-term efficacy profile of this approach, currently considered to be a major progress in neurourology.
Keywords
Botulinum Toxins, Type A/administration & dosage, Botulinum Toxins, Type A/therapeutic use, Humans, Injections, Spinal, Neuromuscular Agents/administration & dosage, Neuromuscular Agents/therapeutic use, Spinal Cord Injuries/complications, Spinal Cord Injuries/physiopathology, Urinary Bladder, Neurogenic/drug therapy, Urinary Bladder, Neurogenic/etiology, Urinary Bladder, Overactive/drug therapy, Urinary Bladder, Overactive/etiology, Urinary Incontinence/drug therapy, Urinary Incontinence/etiology
Pubmed
Web of science
Create date
05/11/2014 12:12
Last modification date
20/08/2019 16:08
Usage data